Literature DB >> 30578959

MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.

Lisa J McReynolds1, Yanqin Yang2, Hong Yuen Wong3, Jingrong Tang3, Yubo Zhang2, Matthew P Mulé3, Janine Daub4, Cindy Palmer4, Ladan Foruraghi4, Qingguo Liu3, Jun Zhu2, Weixin Wang5, Robert R West6, Marielle E Yohe7, Amy P Hsu4, Dennis D Hickstein6, Danielle M Townsley8, Steven M Holland4, Katherine R Calvo5, Christopher S Hourigan3.   

Abstract

Germline mutation in GATA2 can lead to GATA2 deficiency characterized by a complex multi-system disorder that can present with many manifestations including variable cytopenias, bone marrow failure, myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), and severe immunodeficiency. Penetrance and expressivity within families is often variable. There is a spectrum of bone marrow disease in symptomatic cytopenic patients ranging from hypocellular marrows without overt dysplasia to those with definitive MDS, AML, or chronic myelomonocytic leukemia. Relatives of probands with the same mutations may demonstrate minimal disease manifestations and normal marrows. A comprehensive clinical, hematological and genetic assessment of 25 patients with germline GATA2 mutation was performed. MDS-associated mutations were identified in symptomatic GATA2 patients both with overt MDS and in those with hypocellular/aplastic bone marrows without definitive dysplasia. Healthy relatives of probands harboring the same germline GATA2 mutations had essentially normal marrows that were overall devoid of MDS-associated mutations. The findings suggest that abnormal clonal hematopoiesis is a common event in symptomatic germline mutated GATA2 patients with MDS and also in those with hypocellular marrows without overt morphologic evidence of dysplasia, possibly indicating a pre-MDS stage warranting close monitoring for disease progression. Published by Elsevier Ltd.

Entities:  

Keywords:  bone marrow failure; cytogenetics; immunodeficiencies; infectious diseases; molecular genetics; myelodysplastic syndrome

Mesh:

Substances:

Year:  2018        PMID: 30578959      PMCID: PMC6340496          DOI: 10.1016/j.leukres.2018.11.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  20 in total

1.  Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.

Authors:  Katherine R Calvo; Donald C Vinh; Irina Maric; Weixin Wang; Pierre Noel; Maryalice Stetler-Stevenson; Diane C Arthur; Mark Raffeld; Amalia Dutra; Evgenia Pak; Kyungjae Myung; Amy P Hsu; Dennis D Hickstein; Stefania Pittaluga; Steven M Holland
Journal:  Haematologica       Date:  2011-04-20       Impact factor: 9.941

2.  GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.

Authors:  Xinan Wang; Hideki Muramatsu; Yusuke Okuno; Hirotoshi Sakaguchi; Kenichi Yoshida; Nozomu Kawashima; Yinyan Xu; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Shoji Saito; Yozo Nakazawa; Taro Masunari; Tadashi Hirose; Shaimaa Elmahdi; Atsushi Narita; Sayoko Doisaki; Olfat Ismael; Hideki Makishima; Asahito Hama; Satoru Miyano; Yoshiyuki Takahashi; Seishi Ogawa; Seiji Kojima
Journal:  Haematologica       Date:  2015-05-28       Impact factor: 9.941

3.  Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency.

Authors:  Kevin E Fisher; Amy P Hsu; Christopher L Williams; Hadi Sayeed; Brian Y Merritt; M Tarek Elghetany; Steven M Holland; Alison A Bertuch; Maria Monica Gramatges
Journal:  Blood Adv       Date:  2017-02-27

4.  Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome.

Authors:  Michaela Nováková; Markéta Žaliová; Martina Suková; Marcin Wlodarski; Aleš Janda; Eva Froňková; Vít Campr; Kateřina Lejhancová; Ondřej Zapletal; Dagmar Pospíšilová; Zdeňka Černá; Tomáš Kuhn; Peter Švec; Vendula Pelková; Zuzana Zemanová; Gitte Kerndrup; Marry van den Heuvel-Eibrink; Vincent van der Velden; Charlotte Niemeyer; Tomáš Kalina; Jan Trka; Jan Starý; Ondřej Hrušák; Ester Mejstříková
Journal:  Haematologica       Date:  2016-03-24       Impact factor: 9.941

5.  Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.

Authors:  Robert R West; Amy P Hsu; Steven M Holland; Jennifer Cuellar-Rodriguez; Dennis D Hickstein
Journal:  Haematologica       Date:  2013-09-27       Impact factor: 9.941

6.  GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.

Authors:  Karthik A Ganapathi; Danielle M Townsley; Amy P Hsu; Diane C Arthur; Christa S Zerbe; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Sergio D Rosenzweig; Raul C Braylan; Neal S Young; Steven M Holland; Katherine R Calvo
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

7.  Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome).

Authors:  Pia Ostergaard; Michael A Simpson; Fiona C Connell; Colin G Steward; Glen Brice; Wesley J Woollard; Dimitra Dafou; Tatjana Kilo; Sarah Smithson; Peter Lunt; Victoria A Murday; Shirley Hodgson; Russell Keenan; Daniela T Pilz; Ines Martinez-Corral; Taija Makinen; Peter S Mortimer; Steve Jeffery; Richard C Trembath; Sahar Mansour
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

8.  The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency.

Authors:  Venetia Bigley; Muzlifah Haniffa; Sergei Doulatov; Xiao-Nong Wang; Rachel Dickinson; Naomi McGovern; Laura Jardine; Sarah Pagan; Ian Dimmick; Ignatius Chua; Jonathan Wallis; Jim Lordan; Cliff Morgan; Dinakantha S Kumararatne; Rainer Doffinger; Mirjam van der Burg; Jacques van Dongen; Andrew Cant; John E Dick; Sophie Hambleton; Matthew Collin
Journal:  J Exp Med       Date:  2011-01-17       Impact factor: 14.307

Review 9.  Haematopoietic and immune defects associated with GATA2 mutation.

Authors:  Matthew Collin; Rachel Dickinson; Venetia Bigley
Journal:  Br J Haematol       Date:  2015-02-23       Impact factor: 6.998

10.  Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

Authors:  Jean Donadieu; Marie Lamant; Claire Fieschi; Flore Sicre de Fontbrune; Aurélie Caye; Marie Ouachee; Blandine Beaupain; Jacinta Bustamante; Hélène A Poirel; Bertrand Isidor; Eric Van Den Neste; Antoine Neel; Stanislas Nimubona; Fabienne Toutain; Vincent Barlogis; Nicolas Schleinitz; Thierry Leblanc; Pierre Rohrlich; Felipe Suarez; Dana Ranta; Wadih Abou Chahla; Bénédicte Bruno; Louis Terriou; Sylvie Francois; Bruno Lioure; Guido Ahle; Françoise Bachelerie; Claude Preudhomme; Eric Delabesse; Hélène Cave; Christine Bellanné-Chantelot; Marlène Pasquet
Journal:  Haematologica       Date:  2018-05-03       Impact factor: 9.941

View more
  13 in total

Review 1.  The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition.

Authors:  Rashmi Kanagal-Shamanna
Journal:  Curr Hematol Malig Rep       Date:  2021-05-24       Impact factor: 3.952

2.  Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study.

Authors:  Candace L Haddox; Ryan M Carr; Roshini S Abraham; Juliana Perez Botero; Vilmarie Rodriguez; Animesh Pardanani; Mrinal M Patnaik
Journal:  Leuk Lymphoma       Date:  2019-06-27

Review 3.  Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.

Authors:  Kristen E Schratz; Amy E DeZern
Journal:  Hematol Oncol Clin North Am       Date:  2020-01-06       Impact factor: 3.722

4.  Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes.

Authors:  Joseph H Oved; Daria V Babushok; Michele P Lambert; Nicole Wolfset; M Anna Kowalska; Mortimer Poncz; Konrad J Karczewski; Timothy S Olson
Journal:  Blood Adv       Date:  2020-10-27

Review 5.  Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes.

Authors:  Sushree S Sahoo; Emilia J Kozyra; Marcin W Wlodarski
Journal:  Best Pract Res Clin Haematol       Date:  2020-07-29       Impact factor: 3.020

6.  Conditionally pathogenic genetic variants of a hematopoietic disease-suppressing enhancer.

Authors:  Alexandra A Soukup; Daniel R Matson; Peng Liu; Kirby D Johnson; Emery H Bresnick
Journal:  Sci Adv       Date:  2021-12-10       Impact factor: 14.136

7.  ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.

Authors:  Robert R West; Katherine R Calvo; Lisa J Embree; Weixin Wang; Laura M Tuschong; Thomas R Bauer; Desiree Tillo; Justin Lack; Stephenie Droll; Amy P Hsu; Steven M Holland; Dennis D Hickstein
Journal:  Blood Adv       Date:  2022-02-08

Review 8.  Cohesin mutations in myeloid malignancies.

Authors:  Johann-Christoph Jann; Zuzana Tothova
Journal:  Blood       Date:  2021-08-26       Impact factor: 25.476

Review 9.  Clonal hematopoiesis in the inherited bone marrow failure syndromes.

Authors:  Frederick D Tsai; R Coleman Lindsley
Journal:  Blood       Date:  2020-10-01       Impact factor: 25.476

Review 10.  GATA2 +9.5 enhancer: from principles of hematopoiesis to genetic diagnosis in precision medicine.

Authors:  Alexandra A Soukup; Emery H Bresnick
Journal:  Curr Opin Hematol       Date:  2020-05       Impact factor: 3.218

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.